Global Attenuated Vaccine Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
The global market for Attenuated Vaccine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Attenuated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Attenuated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Attenuated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Attenuated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Attenuated Vaccine players cover Merck & Co., GlaxoSmithKline plc, Pfizer Inc, Sanofi and Astellas Pharma, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Attenuated Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Attenuated Vaccine market, with both quantitative and qualitative data, to help readers understand how the Attenuated Vaccine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Doses.
Market Segmentation:
The study segments the Attenuated Vaccine market and forecasts the market size by Type (Bacterial Vaccine and Viral Vaccine,), by Application (Hospital, Clinic and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Chapter 1: Scope of Attenuated Vaccine, Research Methodology, etc.
Chapter 2: Executive Summary, global Attenuated Vaccine market size (sales and revenue) and CAGR, Attenuated Vaccine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Attenuated Vaccine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Attenuated Vaccine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Attenuated Vaccine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Merck & Co., GlaxoSmithKline plc, Pfizer Inc, Sanofi, Astellas Pharma, Johnson & Johnson, CSL Limited, Serum Institute of India Pvt. Ltd. and Biken, etc.
Chapter 14: Research Findings and Conclusion
The global market for Attenuated Vaccine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Attenuated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Attenuated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Attenuated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Attenuated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Attenuated Vaccine players cover Merck & Co., GlaxoSmithKline plc, Pfizer Inc, Sanofi and Astellas Pharma, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Attenuated Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Attenuated Vaccine market, with both quantitative and qualitative data, to help readers understand how the Attenuated Vaccine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Doses.
Market Segmentation:
The study segments the Attenuated Vaccine market and forecasts the market size by Type (Bacterial Vaccine and Viral Vaccine,), by Application (Hospital, Clinic and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
- Bacterial Vaccine
- Viral Vaccine
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck & Co.
- GlaxoSmithKline plc
- Pfizer Inc
- Sanofi
- Astellas Pharma
- Johnson & Johnson
- CSL Limited
- Serum Institute of India Pvt. Ltd.
- Biken
- Green Cross Corporation
- Shanghai Rongsheng Biotech
- Changchun BCHT Biotechnology Co.,Ltd
Chapter 1: Scope of Attenuated Vaccine, Research Methodology, etc.
Chapter 2: Executive Summary, global Attenuated Vaccine market size (sales and revenue) and CAGR, Attenuated Vaccine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Attenuated Vaccine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Attenuated Vaccine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Attenuated Vaccine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Merck & Co., GlaxoSmithKline plc, Pfizer Inc, Sanofi, Astellas Pharma, Johnson & Johnson, CSL Limited, Serum Institute of India Pvt. Ltd. and Biken, etc.
Chapter 14: Research Findings and Conclusion
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Attenuated Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Attenuated Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Attenuated Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Attenuated Vaccine Segment by Type
2.2.1 Bacterial Vaccine
2.2.2 Viral Vaccine
2.3 Attenuated Vaccine Sales by Type
2.3.1 Global Attenuated Vaccine Sales Market Share by Type (2017-2022)
2.3.2 Global Attenuated Vaccine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Attenuated Vaccine Sale Price by Type (2017-2022)
2.4 Attenuated Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Attenuated Vaccine Sales by Application
2.5.1 Global Attenuated Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Attenuated Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Attenuated Vaccine Sale Price by Application (2017-2022)
3 GLOBAL ATTENUATED VACCINE BY COMPANY
3.1 Global Attenuated Vaccine Breakdown Data by Company
3.1.1 Global Attenuated Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Attenuated Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Attenuated Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Attenuated Vaccine Revenue by Company (2020-2022)
3.2.2 Global Attenuated Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Attenuated Vaccine Sale Price by Company
3.4 Key Manufacturers Attenuated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Attenuated Vaccine Product Location Distribution
3.4.2 Players Attenuated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ATTENUATED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Attenuated Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Attenuated Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Attenuated Vaccine Annual Revenue by Geographic Region
4.2 World Historic Attenuated Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Attenuated Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Attenuated Vaccine Annual Revenue by Country/Region
4.3 Americas Attenuated Vaccine Sales Growth
4.4 APAC Attenuated Vaccine Sales Growth
4.5 Europe Attenuated Vaccine Sales Growth
4.6 Middle East & Africa Attenuated Vaccine Sales Growth
5 AMERICAS
5.1 Americas Attenuated Vaccine Sales by Country
5.1.1 Americas Attenuated Vaccine Sales by Country (2017-2022)
5.1.2 Americas Attenuated Vaccine Revenue by Country (2017-2022)
5.2 Americas Attenuated Vaccine Sales by Type
5.3 Americas Attenuated Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Attenuated Vaccine Sales by Region
6.1.1 APAC Attenuated Vaccine Sales by Region (2017-2022)
6.1.2 APAC Attenuated Vaccine Revenue by Region (2017-2022)
6.2 APAC Attenuated Vaccine Sales by Type
6.3 APAC Attenuated Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Attenuated Vaccine by Country
7.1.1 Europe Attenuated Vaccine Sales by Country (2017-2022)
7.1.2 Europe Attenuated Vaccine Revenue by Country (2017-2022)
7.2 Europe Attenuated Vaccine Sales by Type
7.3 Europe Attenuated Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Attenuated Vaccine by Country
8.1.1 Middle East & Africa Attenuated Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Attenuated Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Attenuated Vaccine Sales by Type
8.3 Middle East & Africa Attenuated Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Attenuated Vaccine
10.3 Manufacturing Process Analysis of Attenuated Vaccine
10.4 Industry Chain Structure of Attenuated Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Attenuated Vaccine Distributors
11.3 Attenuated Vaccine Customer
12 WORLD FORECAST REVIEW FOR ATTENUATED VACCINE BY GEOGRAPHIC REGION
12.1 Global Attenuated Vaccine Market Size Forecast by Region
12.1.1 Global Attenuated Vaccine Forecast by Region (2023-2028)
12.1.2 Global Attenuated Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Attenuated Vaccine Forecast by Type
12.7 Global Attenuated Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck & Co.
13.1.1 Merck & Co. Company Information
13.1.2 Merck & Co. Attenuated Vaccine Product Offered
13.1.3 Merck & Co. Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Merck & Co. Main Business Overview
13.1.5 Merck & Co. Latest Developments
13.2 GlaxoSmithKline plc
13.2.1 GlaxoSmithKline plc Company Information
13.2.2 GlaxoSmithKline plc Attenuated Vaccine Product Offered
13.2.3 GlaxoSmithKline plc Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 GlaxoSmithKline plc Main Business Overview
13.2.5 GlaxoSmithKline plc Latest Developments
13.3 Pfizer Inc
13.3.1 Pfizer Inc Company Information
13.3.2 Pfizer Inc Attenuated Vaccine Product Offered
13.3.3 Pfizer Inc Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Pfizer Inc Main Business Overview
13.3.5 Pfizer Inc Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Attenuated Vaccine Product Offered
13.4.3 Sanofi Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Astellas Pharma
13.5.1 Astellas Pharma Company Information
13.5.2 Astellas Pharma Attenuated Vaccine Product Offered
13.5.3 Astellas Pharma Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Astellas Pharma Main Business Overview
13.5.5 Astellas Pharma Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson Attenuated Vaccine Product Offered
13.6.3 Johnson & Johnson Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 CSL Limited
13.7.1 CSL Limited Company Information
13.7.2 CSL Limited Attenuated Vaccine Product Offered
13.7.3 CSL Limited Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 CSL Limited Main Business Overview
13.7.5 CSL Limited Latest Developments
13.8 Serum Institute of India Pvt. Ltd.
13.8.1 Serum Institute of India Pvt. Ltd. Company Information
13.8.2 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Offered
13.8.3 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Serum Institute of India Pvt. Ltd. Main Business Overview
13.8.5 Serum Institute of India Pvt. Ltd. Latest Developments
13.9 Biken
13.9.1 Biken Company Information
13.9.2 Biken Attenuated Vaccine Product Offered
13.9.3 Biken Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Biken Main Business Overview
13.9.5 Biken Latest Developments
13.10 Green Cross Corporation
13.10.1 Green Cross Corporation Company Information
13.10.2 Green Cross Corporation Attenuated Vaccine Product Offered
13.10.3 Green Cross Corporation Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Green Cross Corporation Main Business Overview
13.10.5 Green Cross Corporation Latest Developments
13.11 Shanghai Rongsheng Biotech
13.11.1 Shanghai Rongsheng Biotech Company Information
13.11.2 Shanghai Rongsheng Biotech Attenuated Vaccine Product Offered
13.11.3 Shanghai Rongsheng Biotech Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Shanghai Rongsheng Biotech Main Business Overview
13.11.5 Shanghai Rongsheng Biotech Latest Developments
13.12 Changchun BCHT Biotechnology Co.,Ltd
13.12.1 Changchun BCHT Biotechnology Co.,Ltd Company Information
13.12.2 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Offered
13.12.3 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Changchun BCHT Biotechnology Co.,Ltd Main Business Overview
13.12.5 Changchun BCHT Biotechnology Co.,Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Attenuated Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Attenuated Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Attenuated Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Attenuated Vaccine Segment by Type
2.2.1 Bacterial Vaccine
2.2.2 Viral Vaccine
2.3 Attenuated Vaccine Sales by Type
2.3.1 Global Attenuated Vaccine Sales Market Share by Type (2017-2022)
2.3.2 Global Attenuated Vaccine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Attenuated Vaccine Sale Price by Type (2017-2022)
2.4 Attenuated Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Attenuated Vaccine Sales by Application
2.5.1 Global Attenuated Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Attenuated Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Attenuated Vaccine Sale Price by Application (2017-2022)
3 GLOBAL ATTENUATED VACCINE BY COMPANY
3.1 Global Attenuated Vaccine Breakdown Data by Company
3.1.1 Global Attenuated Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Attenuated Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Attenuated Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Attenuated Vaccine Revenue by Company (2020-2022)
3.2.2 Global Attenuated Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Attenuated Vaccine Sale Price by Company
3.4 Key Manufacturers Attenuated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Attenuated Vaccine Product Location Distribution
3.4.2 Players Attenuated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ATTENUATED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Attenuated Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Attenuated Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Attenuated Vaccine Annual Revenue by Geographic Region
4.2 World Historic Attenuated Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Attenuated Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Attenuated Vaccine Annual Revenue by Country/Region
4.3 Americas Attenuated Vaccine Sales Growth
4.4 APAC Attenuated Vaccine Sales Growth
4.5 Europe Attenuated Vaccine Sales Growth
4.6 Middle East & Africa Attenuated Vaccine Sales Growth
5 AMERICAS
5.1 Americas Attenuated Vaccine Sales by Country
5.1.1 Americas Attenuated Vaccine Sales by Country (2017-2022)
5.1.2 Americas Attenuated Vaccine Revenue by Country (2017-2022)
5.2 Americas Attenuated Vaccine Sales by Type
5.3 Americas Attenuated Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Attenuated Vaccine Sales by Region
6.1.1 APAC Attenuated Vaccine Sales by Region (2017-2022)
6.1.2 APAC Attenuated Vaccine Revenue by Region (2017-2022)
6.2 APAC Attenuated Vaccine Sales by Type
6.3 APAC Attenuated Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Attenuated Vaccine by Country
7.1.1 Europe Attenuated Vaccine Sales by Country (2017-2022)
7.1.2 Europe Attenuated Vaccine Revenue by Country (2017-2022)
7.2 Europe Attenuated Vaccine Sales by Type
7.3 Europe Attenuated Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Attenuated Vaccine by Country
8.1.1 Middle East & Africa Attenuated Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Attenuated Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Attenuated Vaccine Sales by Type
8.3 Middle East & Africa Attenuated Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Attenuated Vaccine
10.3 Manufacturing Process Analysis of Attenuated Vaccine
10.4 Industry Chain Structure of Attenuated Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Attenuated Vaccine Distributors
11.3 Attenuated Vaccine Customer
12 WORLD FORECAST REVIEW FOR ATTENUATED VACCINE BY GEOGRAPHIC REGION
12.1 Global Attenuated Vaccine Market Size Forecast by Region
12.1.1 Global Attenuated Vaccine Forecast by Region (2023-2028)
12.1.2 Global Attenuated Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Attenuated Vaccine Forecast by Type
12.7 Global Attenuated Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck & Co.
13.1.1 Merck & Co. Company Information
13.1.2 Merck & Co. Attenuated Vaccine Product Offered
13.1.3 Merck & Co. Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Merck & Co. Main Business Overview
13.1.5 Merck & Co. Latest Developments
13.2 GlaxoSmithKline plc
13.2.1 GlaxoSmithKline plc Company Information
13.2.2 GlaxoSmithKline plc Attenuated Vaccine Product Offered
13.2.3 GlaxoSmithKline plc Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 GlaxoSmithKline plc Main Business Overview
13.2.5 GlaxoSmithKline plc Latest Developments
13.3 Pfizer Inc
13.3.1 Pfizer Inc Company Information
13.3.2 Pfizer Inc Attenuated Vaccine Product Offered
13.3.3 Pfizer Inc Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Pfizer Inc Main Business Overview
13.3.5 Pfizer Inc Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Attenuated Vaccine Product Offered
13.4.3 Sanofi Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Astellas Pharma
13.5.1 Astellas Pharma Company Information
13.5.2 Astellas Pharma Attenuated Vaccine Product Offered
13.5.3 Astellas Pharma Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Astellas Pharma Main Business Overview
13.5.5 Astellas Pharma Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson Attenuated Vaccine Product Offered
13.6.3 Johnson & Johnson Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 CSL Limited
13.7.1 CSL Limited Company Information
13.7.2 CSL Limited Attenuated Vaccine Product Offered
13.7.3 CSL Limited Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 CSL Limited Main Business Overview
13.7.5 CSL Limited Latest Developments
13.8 Serum Institute of India Pvt. Ltd.
13.8.1 Serum Institute of India Pvt. Ltd. Company Information
13.8.2 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Offered
13.8.3 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Serum Institute of India Pvt. Ltd. Main Business Overview
13.8.5 Serum Institute of India Pvt. Ltd. Latest Developments
13.9 Biken
13.9.1 Biken Company Information
13.9.2 Biken Attenuated Vaccine Product Offered
13.9.3 Biken Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Biken Main Business Overview
13.9.5 Biken Latest Developments
13.10 Green Cross Corporation
13.10.1 Green Cross Corporation Company Information
13.10.2 Green Cross Corporation Attenuated Vaccine Product Offered
13.10.3 Green Cross Corporation Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Green Cross Corporation Main Business Overview
13.10.5 Green Cross Corporation Latest Developments
13.11 Shanghai Rongsheng Biotech
13.11.1 Shanghai Rongsheng Biotech Company Information
13.11.2 Shanghai Rongsheng Biotech Attenuated Vaccine Product Offered
13.11.3 Shanghai Rongsheng Biotech Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Shanghai Rongsheng Biotech Main Business Overview
13.11.5 Shanghai Rongsheng Biotech Latest Developments
13.12 Changchun BCHT Biotechnology Co.,Ltd
13.12.1 Changchun BCHT Biotechnology Co.,Ltd Company Information
13.12.2 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Offered
13.12.3 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Changchun BCHT Biotechnology Co.,Ltd Main Business Overview
13.12.5 Changchun BCHT Biotechnology Co.,Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Attenuated Vaccine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Attenuated Vaccine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Bacterial Vaccine
Table 4. Major Players of Viral Vaccine
Table 5. Global Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 6. Global Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 7. Global Attenuated Vaccine Revenue by Type (2017-2022) & ($ million)
Table 8. Global Attenuated Vaccine Revenue Market Share by Type (2017-2022)
Table 9. Global Attenuated Vaccine Sale Price by Type (2017-2022) & (US$/Dose)
Table 10. Global Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 11. Global Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 12. Global Attenuated Vaccine Revenue by Application (2017-2022)
Table 13. Global Attenuated Vaccine Revenue Market Share by Application (2017-2022)
Table 14. Global Attenuated Vaccine Sale Price by Application (2017-2022) & (US$/Dose)
Table 15. Global Attenuated Vaccine Sales by Company (2020-2022) & (K Doses)
Table 16. Global Attenuated Vaccine Sales Market Share by Company (2020-2022)
Table 17. Global Attenuated Vaccine Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Attenuated Vaccine Revenue Market Share by Company (2020-2022)
Table 19. Global Attenuated Vaccine Sale Price by Company (2020-2022) & (US$/Dose)
Table 20. Key Manufacturers Attenuated Vaccine Producing Area Distribution and Sales Area
Table 21. Players Attenuated Vaccine Products Offered
Table 22. Attenuated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Attenuated Vaccine Sales by Geographic Region (2017-2022) & (K Doses)
Table 26. Global Attenuated Vaccine Sales Market Share Geographic Region (2017-2022)
Table 27. Global Attenuated Vaccine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Attenuated Vaccine Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Attenuated Vaccine Sales by Country/Region (2017-2022) & (K Doses)
Table 30. Global Attenuated Vaccine Sales Market Share by Country/Region (2017-2022)
Table 31. Global Attenuated Vaccine Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Attenuated Vaccine Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Attenuated Vaccine Sales by Country (2017-2022) & (K Doses)
Table 34. Americas Attenuated Vaccine Sales Market Share by Country (2017-2022)
Table 35. Americas Attenuated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Attenuated Vaccine Revenue Market Share by Country (2017-2022)
Table 37. Americas Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 38. Americas Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 39. Americas Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 40. Americas Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 41. APAC Attenuated Vaccine Sales by Region (2017-2022) & (K Doses)
Table 42. APAC Attenuated Vaccine Sales Market Share by Region (2017-2022)
Table 43. APAC Attenuated Vaccine Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Attenuated Vaccine Revenue Market Share by Region (2017-2022)
Table 45. APAC Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 46. APAC Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 47. APAC Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 48. APAC Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 49. Europe Attenuated Vaccine Sales by Country (2017-2022) & (K Doses)
Table 50. Europe Attenuated Vaccine Sales Market Share by Country (2017-2022)
Table 51. Europe Attenuated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Attenuated Vaccine Revenue Market Share by Country (2017-2022)
Table 53. Europe Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 54. Europe Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 55. Europe Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 56. Europe Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Attenuated Vaccine Sales by Country (2017-2022) & (K Doses)
Table 58. Middle East & Africa Attenuated Vaccine Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Attenuated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Attenuated Vaccine Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 62. Middle East & Africa Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 64. Middle East & Africa Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Attenuated Vaccine
Table 66. Key Market Challenges & Risks of Attenuated Vaccine
Table 67. Key Industry Trends of Attenuated Vaccine
Table 68. Attenuated Vaccine Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Attenuated Vaccine Distributors List
Table 71. Attenuated Vaccine Customer List
Table 72. Global Attenuated Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 73. Global Attenuated Vaccine Sales Market Forecast by Region
Table 74. Global Attenuated Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Attenuated Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Attenuated Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 77. Americas Attenuated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Attenuated Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 79. APAC Attenuated Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Attenuated Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 81. Europe Attenuated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Attenuated Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 83. Middle East & Africa Attenuated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Attenuated Vaccine Sales Forecast by Type (2023-2028) & (K Doses)
Table 85. Global Attenuated Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Attenuated Vaccine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Attenuated Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Attenuated Vaccine Sales Forecast by Application (2023-2028) & (K Doses)
Table 89. Global Attenuated Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Attenuated Vaccine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Attenuated Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 92. Merck & Co. Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck & Co. Attenuated Vaccine Product Offered
Table 94. Merck & Co. Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 95. Merck & Co. Main Business
Table 96. Merck & Co. Latest Developments
Table 97. GlaxoSmithKline plc Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. GlaxoSmithKline plc Attenuated Vaccine Product Offered
Table 99. GlaxoSmithKline plc Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 100. GlaxoSmithKline plc Main Business
Table 101. GlaxoSmithKline plc Latest Developments
Table 102. Pfizer Inc Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Pfizer Inc Attenuated Vaccine Product Offered
Table 104. Pfizer Inc Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 105. Pfizer Inc Main Business
Table 106. Pfizer Inc Latest Developments
Table 107. Sanofi Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Sanofi Attenuated Vaccine Product Offered
Table 109. Sanofi Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 110. Sanofi Main Business
Table 111. Sanofi Latest Developments
Table 112. Astellas Pharma Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Astellas Pharma Attenuated Vaccine Product Offered
Table 114. Astellas Pharma Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 115. Astellas Pharma Main Business
Table 116. Astellas Pharma Latest Developments
Table 117. Johnson & Johnson Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Johnson & Johnson Attenuated Vaccine Product Offered
Table 119. Johnson & Johnson Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 120. Johnson & Johnson Main Business
Table 121. Johnson & Johnson Latest Developments
Table 122. CSL Limited Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. CSL Limited Attenuated Vaccine Product Offered
Table 124. CSL Limited Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 125. CSL Limited Main Business
Table 126. CSL Limited Latest Developments
Table 127. Serum Institute of India Pvt. Ltd. Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Offered
Table 129. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 130. Serum Institute of India Pvt. Ltd. Main Business
Table 131. Serum Institute of India Pvt. Ltd. Latest Developments
Table 132. Biken Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 133. Biken Attenuated Vaccine Product Offered
Table 134. Biken Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 135. Biken Main Business
Table 136. Biken Latest Developments
Table 137. Green Cross Corporation Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 138. Green Cross Corporation Attenuated Vaccine Product Offered
Table 139. Green Cross Corporation Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 140. Green Cross Corporation Main Business
Table 141. Green Cross Corporation Latest Developments
Table 142. Shanghai Rongsheng Biotech Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 143. Shanghai Rongsheng Biotech Attenuated Vaccine Product Offered
Table 144. Shanghai Rongsheng Biotech Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 145. Shanghai Rongsheng Biotech Main Business
Table 146. Shanghai Rongsheng Biotech Latest Developments
Table 147. Changchun BCHT Biotechnology Co.,Ltd Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 148. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Offered
Table 149. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 150. Changchun BCHT Biotechnology Co.,Ltd Main Business
Table 151. Changchun BCHT Biotechnology Co.,Ltd Latest Developments
Table 1. Attenuated Vaccine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Attenuated Vaccine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Bacterial Vaccine
Table 4. Major Players of Viral Vaccine
Table 5. Global Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 6. Global Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 7. Global Attenuated Vaccine Revenue by Type (2017-2022) & ($ million)
Table 8. Global Attenuated Vaccine Revenue Market Share by Type (2017-2022)
Table 9. Global Attenuated Vaccine Sale Price by Type (2017-2022) & (US$/Dose)
Table 10. Global Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 11. Global Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 12. Global Attenuated Vaccine Revenue by Application (2017-2022)
Table 13. Global Attenuated Vaccine Revenue Market Share by Application (2017-2022)
Table 14. Global Attenuated Vaccine Sale Price by Application (2017-2022) & (US$/Dose)
Table 15. Global Attenuated Vaccine Sales by Company (2020-2022) & (K Doses)
Table 16. Global Attenuated Vaccine Sales Market Share by Company (2020-2022)
Table 17. Global Attenuated Vaccine Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Attenuated Vaccine Revenue Market Share by Company (2020-2022)
Table 19. Global Attenuated Vaccine Sale Price by Company (2020-2022) & (US$/Dose)
Table 20. Key Manufacturers Attenuated Vaccine Producing Area Distribution and Sales Area
Table 21. Players Attenuated Vaccine Products Offered
Table 22. Attenuated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Attenuated Vaccine Sales by Geographic Region (2017-2022) & (K Doses)
Table 26. Global Attenuated Vaccine Sales Market Share Geographic Region (2017-2022)
Table 27. Global Attenuated Vaccine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Attenuated Vaccine Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Attenuated Vaccine Sales by Country/Region (2017-2022) & (K Doses)
Table 30. Global Attenuated Vaccine Sales Market Share by Country/Region (2017-2022)
Table 31. Global Attenuated Vaccine Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Attenuated Vaccine Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Attenuated Vaccine Sales by Country (2017-2022) & (K Doses)
Table 34. Americas Attenuated Vaccine Sales Market Share by Country (2017-2022)
Table 35. Americas Attenuated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Attenuated Vaccine Revenue Market Share by Country (2017-2022)
Table 37. Americas Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 38. Americas Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 39. Americas Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 40. Americas Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 41. APAC Attenuated Vaccine Sales by Region (2017-2022) & (K Doses)
Table 42. APAC Attenuated Vaccine Sales Market Share by Region (2017-2022)
Table 43. APAC Attenuated Vaccine Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Attenuated Vaccine Revenue Market Share by Region (2017-2022)
Table 45. APAC Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 46. APAC Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 47. APAC Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 48. APAC Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 49. Europe Attenuated Vaccine Sales by Country (2017-2022) & (K Doses)
Table 50. Europe Attenuated Vaccine Sales Market Share by Country (2017-2022)
Table 51. Europe Attenuated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Attenuated Vaccine Revenue Market Share by Country (2017-2022)
Table 53. Europe Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 54. Europe Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 55. Europe Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 56. Europe Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Attenuated Vaccine Sales by Country (2017-2022) & (K Doses)
Table 58. Middle East & Africa Attenuated Vaccine Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Attenuated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Attenuated Vaccine Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Attenuated Vaccine Sales by Type (2017-2022) & (K Doses)
Table 62. Middle East & Africa Attenuated Vaccine Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Attenuated Vaccine Sales by Application (2017-2022) & (K Doses)
Table 64. Middle East & Africa Attenuated Vaccine Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Attenuated Vaccine
Table 66. Key Market Challenges & Risks of Attenuated Vaccine
Table 67. Key Industry Trends of Attenuated Vaccine
Table 68. Attenuated Vaccine Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Attenuated Vaccine Distributors List
Table 71. Attenuated Vaccine Customer List
Table 72. Global Attenuated Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 73. Global Attenuated Vaccine Sales Market Forecast by Region
Table 74. Global Attenuated Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Attenuated Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Attenuated Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 77. Americas Attenuated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Attenuated Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 79. APAC Attenuated Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Attenuated Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 81. Europe Attenuated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Attenuated Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 83. Middle East & Africa Attenuated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Attenuated Vaccine Sales Forecast by Type (2023-2028) & (K Doses)
Table 85. Global Attenuated Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Attenuated Vaccine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Attenuated Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Attenuated Vaccine Sales Forecast by Application (2023-2028) & (K Doses)
Table 89. Global Attenuated Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Attenuated Vaccine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Attenuated Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 92. Merck & Co. Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck & Co. Attenuated Vaccine Product Offered
Table 94. Merck & Co. Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 95. Merck & Co. Main Business
Table 96. Merck & Co. Latest Developments
Table 97. GlaxoSmithKline plc Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. GlaxoSmithKline plc Attenuated Vaccine Product Offered
Table 99. GlaxoSmithKline plc Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 100. GlaxoSmithKline plc Main Business
Table 101. GlaxoSmithKline plc Latest Developments
Table 102. Pfizer Inc Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Pfizer Inc Attenuated Vaccine Product Offered
Table 104. Pfizer Inc Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 105. Pfizer Inc Main Business
Table 106. Pfizer Inc Latest Developments
Table 107. Sanofi Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Sanofi Attenuated Vaccine Product Offered
Table 109. Sanofi Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 110. Sanofi Main Business
Table 111. Sanofi Latest Developments
Table 112. Astellas Pharma Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Astellas Pharma Attenuated Vaccine Product Offered
Table 114. Astellas Pharma Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 115. Astellas Pharma Main Business
Table 116. Astellas Pharma Latest Developments
Table 117. Johnson & Johnson Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Johnson & Johnson Attenuated Vaccine Product Offered
Table 119. Johnson & Johnson Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 120. Johnson & Johnson Main Business
Table 121. Johnson & Johnson Latest Developments
Table 122. CSL Limited Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. CSL Limited Attenuated Vaccine Product Offered
Table 124. CSL Limited Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 125. CSL Limited Main Business
Table 126. CSL Limited Latest Developments
Table 127. Serum Institute of India Pvt. Ltd. Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Offered
Table 129. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 130. Serum Institute of India Pvt. Ltd. Main Business
Table 131. Serum Institute of India Pvt. Ltd. Latest Developments
Table 132. Biken Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 133. Biken Attenuated Vaccine Product Offered
Table 134. Biken Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 135. Biken Main Business
Table 136. Biken Latest Developments
Table 137. Green Cross Corporation Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 138. Green Cross Corporation Attenuated Vaccine Product Offered
Table 139. Green Cross Corporation Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 140. Green Cross Corporation Main Business
Table 141. Green Cross Corporation Latest Developments
Table 142. Shanghai Rongsheng Biotech Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 143. Shanghai Rongsheng Biotech Attenuated Vaccine Product Offered
Table 144. Shanghai Rongsheng Biotech Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 145. Shanghai Rongsheng Biotech Main Business
Table 146. Shanghai Rongsheng Biotech Latest Developments
Table 147. Changchun BCHT Biotechnology Co.,Ltd Basic Information, Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 148. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Offered
Table 149. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 150. Changchun BCHT Biotechnology Co.,Ltd Main Business
Table 151. Changchun BCHT Biotechnology Co.,Ltd Latest Developments
LIST OF FIGURES
Figure 1. Picture of Attenuated Vaccine
Figure 2. Attenuated Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Attenuated Vaccine Sales Growth Rate 2017-2028 (K Doses)
Figure 7. Global Attenuated Vaccine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Attenuated Vaccine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Bacterial Vaccine
Figure 10. Product Picture of Viral Vaccine
Figure 11. Global Attenuated Vaccine Sales Market Share by Type in 2021
Figure 12. Global Attenuated Vaccine Revenue Market Share by Type (2017-2022)
Figure 13. Attenuated Vaccine Consumed in Hospital
Figure 14. Global Attenuated Vaccine Market: Hospital (2017-2022) & (K Doses)
Figure 15. Attenuated Vaccine Consumed in Clinic
Figure 16. Global Attenuated Vaccine Market: Clinic (2017-2022) & (K Doses)
Figure 17. Attenuated Vaccine Consumed in Others
Figure 18. Global Attenuated Vaccine Market: Others (2017-2022) & (K Doses)
Figure 19. Global Attenuated Vaccine Sales Market Share by Application (2017-2022)
Figure 20. Global Attenuated Vaccine Revenue Market Share by Application in 2021
Figure 21. Attenuated Vaccine Revenue Market by Company in 2021 ($ Million)
Figure 22. Global Attenuated Vaccine Revenue Market Share by Company in 2021
Figure 23. Global Attenuated Vaccine Sales Market Share by Geographic Region (2017-2022)
Figure 24. Global Attenuated Vaccine Revenue Market Share by Geographic Region in 2021
Figure 25. Global Attenuated Vaccine Sales Market Share by Region (2017-2022)
Figure 26. Global Attenuated Vaccine Revenue Market Share by Country/Region in 2021
Figure 27. Americas Attenuated Vaccine Sales 2017-2022 (K Doses)
Figure 28. Americas Attenuated Vaccine Revenue 2017-2022 ($ Millions)
Figure 29. APAC Attenuated Vaccine Sales 2017-2022 (K Doses)
Figure 30. APAC Attenuated Vaccine Revenue 2017-2022 ($ Millions)
Figure 31. Europe Attenuated Vaccine Sales 2017-2022 (K Doses)
Figure 32. Europe Attenuated Vaccine Revenue 2017-2022 ($ Millions)
Figure 33. Middle East & Africa Attenuated Vaccine Sales 2017-2022 (K Doses)
Figure 34. Middle East & Africa Attenuated Vaccine Revenue 2017-2022 ($ Millions)
Figure 35. Americas Attenuated Vaccine Sales Market Share by Country in 2021
Figure 36. Americas Attenuated Vaccine Revenue Market Share by Country in 2021
Figure 37. United States Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 38. Canada Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 39. Mexico Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 40. Brazil Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 41. APAC Attenuated Vaccine Sales Market Share by Region in 2021
Figure 42. APAC Attenuated Vaccine Revenue Market Share by Regions in 2021
Figure 43. China Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 44. Japan Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 45. South Korea Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 46. Southeast Asia Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 47. India Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 48. Australia Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 49. Europe Attenuated Vaccine Sales Market Share by Country in 2021
Figure 50. Europe Attenuated Vaccine Revenue Market Share by Country in 2021
Figure 51. Germany Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 52. France Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 53. UK Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Italy Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 55. Russia Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 56. Middle East & Africa Attenuated Vaccine Sales Market Share by Country in 2021
Figure 57. Middle East & Africa Attenuated Vaccine Revenue Market Share by Country in 2021
Figure 58. Egypt Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 59. South Africa Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 60. Israel Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 61. Turkey Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 62. GCC Country Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 63. Manufacturing Cost Structure Analysis of Attenuated Vaccine in 2021
Figure 64. Manufacturing Process Analysis of Attenuated Vaccine
Figure 65. Industry Chain Structure of Attenuated Vaccine
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles
Figure 1. Picture of Attenuated Vaccine
Figure 2. Attenuated Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Attenuated Vaccine Sales Growth Rate 2017-2028 (K Doses)
Figure 7. Global Attenuated Vaccine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Attenuated Vaccine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Bacterial Vaccine
Figure 10. Product Picture of Viral Vaccine
Figure 11. Global Attenuated Vaccine Sales Market Share by Type in 2021
Figure 12. Global Attenuated Vaccine Revenue Market Share by Type (2017-2022)
Figure 13. Attenuated Vaccine Consumed in Hospital
Figure 14. Global Attenuated Vaccine Market: Hospital (2017-2022) & (K Doses)
Figure 15. Attenuated Vaccine Consumed in Clinic
Figure 16. Global Attenuated Vaccine Market: Clinic (2017-2022) & (K Doses)
Figure 17. Attenuated Vaccine Consumed in Others
Figure 18. Global Attenuated Vaccine Market: Others (2017-2022) & (K Doses)
Figure 19. Global Attenuated Vaccine Sales Market Share by Application (2017-2022)
Figure 20. Global Attenuated Vaccine Revenue Market Share by Application in 2021
Figure 21. Attenuated Vaccine Revenue Market by Company in 2021 ($ Million)
Figure 22. Global Attenuated Vaccine Revenue Market Share by Company in 2021
Figure 23. Global Attenuated Vaccine Sales Market Share by Geographic Region (2017-2022)
Figure 24. Global Attenuated Vaccine Revenue Market Share by Geographic Region in 2021
Figure 25. Global Attenuated Vaccine Sales Market Share by Region (2017-2022)
Figure 26. Global Attenuated Vaccine Revenue Market Share by Country/Region in 2021
Figure 27. Americas Attenuated Vaccine Sales 2017-2022 (K Doses)
Figure 28. Americas Attenuated Vaccine Revenue 2017-2022 ($ Millions)
Figure 29. APAC Attenuated Vaccine Sales 2017-2022 (K Doses)
Figure 30. APAC Attenuated Vaccine Revenue 2017-2022 ($ Millions)
Figure 31. Europe Attenuated Vaccine Sales 2017-2022 (K Doses)
Figure 32. Europe Attenuated Vaccine Revenue 2017-2022 ($ Millions)
Figure 33. Middle East & Africa Attenuated Vaccine Sales 2017-2022 (K Doses)
Figure 34. Middle East & Africa Attenuated Vaccine Revenue 2017-2022 ($ Millions)
Figure 35. Americas Attenuated Vaccine Sales Market Share by Country in 2021
Figure 36. Americas Attenuated Vaccine Revenue Market Share by Country in 2021
Figure 37. United States Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 38. Canada Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 39. Mexico Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 40. Brazil Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 41. APAC Attenuated Vaccine Sales Market Share by Region in 2021
Figure 42. APAC Attenuated Vaccine Revenue Market Share by Regions in 2021
Figure 43. China Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 44. Japan Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 45. South Korea Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 46. Southeast Asia Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 47. India Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 48. Australia Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 49. Europe Attenuated Vaccine Sales Market Share by Country in 2021
Figure 50. Europe Attenuated Vaccine Revenue Market Share by Country in 2021
Figure 51. Germany Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 52. France Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 53. UK Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Italy Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 55. Russia Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 56. Middle East & Africa Attenuated Vaccine Sales Market Share by Country in 2021
Figure 57. Middle East & Africa Attenuated Vaccine Revenue Market Share by Country in 2021
Figure 58. Egypt Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 59. South Africa Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 60. Israel Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 61. Turkey Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 62. GCC Country Attenuated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 63. Manufacturing Cost Structure Analysis of Attenuated Vaccine in 2021
Figure 64. Manufacturing Process Analysis of Attenuated Vaccine
Figure 65. Industry Chain Structure of Attenuated Vaccine
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles
